The 2020 new global cancer data released by the International Agency for Research on Cancer (IARC) showed that there were 19.29 million new cases and 9.96 million cancer deaths worldwide in 2020, including 4.57 million new cases (23.7%) and 3.00 million cancer deaths (30%) in China, ranking first in the world.

   根据世界卫生组织国际癌症研究中心（IARC）最新发布的 2020 年全球最新癌症负担数据，2020 年全球癌症新发病例和死亡病例分别为 1929 万例、996 万例，其中中国新发癌症病例和死亡病例分别为 457 万例、300 万例，分别占比 23.7%、30%，均位居全球第一。

As aged tendency of the Chinese population and urbanization have been accelerated, thus the new cancer cases every year have become a great challenge to the field of health development in China. The huge number of cancer patients in China has become a barrier to achieve the magnificent goal of "Healthy China".

随着中国人口老龄化和城市化进程加速，每年的新增肿瘤病例已成为我国医疗卫生行业健康发展的巨大挑战。我国的庞大肿瘤患者数量，已成为实现“健康中国”宏伟目标需要攻破的壁垒。

Tumor prevention and control are the important measures to improve national health. "The Healthy China 2030 Plan" indicates that the average life expectancy in China will reach 79 years by 2030, while the 2019 "State Council's Opinions on Implementing Healthy China Initiative" has further proposed that the five-year survival rate of cancer patients should be increased by 15%, and the overall five-year survival rate of cancer patients should not be less than 46.6% by 2030.

肿瘤防控是改善国民健康水平重要措施。《“健康中国2030”规划纲要》中指出，中国的人均预期寿命在2030年要达到79岁；而国务院2019年发布的《关于实施健康中国行动的意见》里，也进一步提出，将肿瘤患者的五年生存率提升15%，到2030年总体癌症5年生存率不低于46.6%的目标。

Malignant tumor is usually developed by genetic variation.Sporadic tumor is polygenetic disease with complex pathogenesis, which bring great challenge to the prevention, diagnosis and treatment of the tumor. In contrast, hereditary tumor is transmittable in family, caused by germline mutation in cancer genes, and thus traceable in the patient's family.

恶性肿瘤的发生通常伴随基因的变异。散发性肿瘤是多基因疾病，发病机制复杂，给肿瘤的预防和诊治带来了极大的挑战。相比之下，遗传性肿瘤呈家族传递，其发生是因固有的肿瘤基因胚系变异所致，在患者的家族里有源可循。

Therefore, hereditary tumor is a kind of preventable and controllable disease, and passage of mutated genes to offspring can be effectively blocked by analysis of risk of hereditary tumor, prenatal diagnosis (PD), and preimplantation genetic test (PGT). In addition, cancer genetic counseling can help the public to get correct cancer risk assessment and prevention guidance, therefore facilitating effective genetic screening and testing, also providing professional and standardized management services to carriers for tumorigenesis, in order to reduce the development of malignant tumors.

因此，遗传性肿瘤是一类可防可控的疾病，通过对遗传性肿瘤患病风险的测算、产前诊断或胚胎植入前遗传学检测等手段可有效阻断变异基因往后代传递。此外，肿瘤遗传咨询可以帮助大众得到对遗传性肿瘤正确的患癌风险评估和预防指导，做好遗传筛查和预防，对携带者提供相关肿瘤发生专业规范性的监测和管理服务，从而降低恶性肿瘤发生可能性。

In order to promote international academic exchanges, and prevention and control of hereditary tumors in China, the 2022 ICPCHC held by Zhongnanshan Medical Foundation of Guangdong Province, in combination with ZaoDx.com and other units, sincerely invites authoritative experts, scholars and industry elites at home and abroad, to discuss the prevention and control of hereditary tumors.

为促进国际学术交流、推动中国遗传性肿瘤防控，由广东省钟南山医学基金会联合早筛网等单位举办“2023国际遗传性肿瘤防控高峰论坛暨2023中国基因检测临床应用前沿论坛”，诚邀国内外权威专家学者、行业菁英，共同探讨遗传性肿瘤防控工作发展进程。

2023 International Conference on Prevention and Control of Hereditary Cancers

(2023 ICPCHC)

1. Date: March 26th , 2023

2. Location: Four Points by Sheraton Guangzhou,Dongpu（ Hall A）（No.1,Jingying Road,Huicai Road,Dongpu Tianhe District, Guangzhou）

3. Organizers: Zhongnanshan Medical Foundation of Guangdong Province, ZaoDx.com, GeneNewsWire

4. Conference Attendant scale: 200+ on-site attendances & multi-platform live video

2023国际遗传性肿瘤防控高峰论坛

1.时间：2023年3月26日

2.地点：广州东圃福朋喜来登酒店福朋宴会厅 A厅

3.主办单位：广东省钟南山医学基金会、早筛网、基因科技网

4.会议规模：线下200人+线上多平台直播

Registration/参会通道

1、QR code/扫描下方二维码参加线上/线下会议

2、Link/复制下方链接到新建网页打开

On-Line / 线上参会通道：

https://wx.vzan.com/live/page/6FBE2681336A78AF181C44D2D5C075B4?topicid=1139264896&v=1667981896069&ver=3a1507d66947410080bdf62c1d0d0227

On-Site / 线下参会通道:

https://www.huodongxing.com/event/4670093266200